1	UNITED STATES PATENT AND TRADEMARK OFFICE
2	
3	BEFORE THE PATENT TRIAL AND APPEAL BOARD
4	
5	MYLAN PHARMACEUTICALS, INC.,
6	Petitioners,
7	V.
8	NOVO NORDISK A/S,
9	Patent Owner.
10	
11	Case IPR2023-00724
12	U.S. Patent No. 10,335,462
13	
14	Deposition of STEVEN COCA, D.O., M.D.
15	Conducted Virtually
16	Tuesday, July,16, 2024
17	10:03 a.m. EDT
18	Job No.: 543599
19	Pages: 1 - 159
20	Stenographically reported by: Judith E. Bellinger,
21	RPR, CRR, CSR-TX CCR-WA, CCR-NM
22	Reported by: Judith E. Bellinger, RPR, CRR



```
Deposition of STEVEN COCA, D.O., M.D.,
1
2
    conducted virtually.
3
4
5
6
7
8
9
10
         Pursuant to notice, before Judith E.
11
    Bellinger, Registered Professional Reporter,
12
13
    Certified Realtime Reporter, and Notary Public in
    and for the State of Maryland.
14
15
16
17
18
19
20
21
22
```



4				
1	APPEARANCES			
2	ON BEHALF OF THE PETITIONERS:			
3	DAVID ANSTAETT, ESQUIRE			
4	CHRISTOPHER JONES, ESQUIRE			
5	PERKINS COI LLP			
6	33 East Main Street			
7	Suite 201			
8	Madison, WI 53703			
9	608.663.7460			
10				
11	ON BEHALF OF THE PATENT OWNER:			
12	JOSHUA D. REICH, ESQUIRE			
13	GROOMBRIDGE, WU, BAUGHMAN & STONE LLP			
14	565 Fifth Avenue			
15	New York, NY 10017			
16	332.269.0030			
17				
18	J. STEVEN BAUGHMAN, ESQUIRE			
19	GROOMBRIDGE, WU, BAUGHMAN & STONE LLP			
20	801 17th			
21	Washington, DC 20006			
22	202.505.5830			



```
APPEARANCES
1
                                CONTINUED
2
3
    ALSO PRESENT:
         Sean, Planet Depos Technician
4
5
         Preston Imperatore - In-house counsel, Mylan
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
```



1					
1	CONTENTS				
2	EXAMINATION OF STEVEN COCA, PH.D. PAG				
3	By Mr. Reich 7				
4	By Mr. Anstaett 148				
5	EXHIBITS				
6	(Attached to the transcript)				
7	Coca Exhibits: PAGE				
8	Exhibit 1	United States Patent Number	21		
9		10,335,462 B2			
10	Exhibit 2	Declaration of Steven G. Coca, D.O.,	27		
11		M.D.			
12	Exhibit 3	Antihypertensive effect of	44		
13		glucagon-like peptide 1 in Dahl			
14		salt-sensitive rats			
15	Exhibit 4	Anti-hypertensive and natriuretic	50		
16		effect of a glucagon-like peptide 1			
17		in Dahl S rats: a novel function for	-		
18		a pleotrophic hormone?			
19	Exhibit 5	Glucagon-Like Peptide 1 Induces	57		
20		Natriuresis in Healthy Subjects and			
21		in Insulin-Resistant Obese Men			
22					



DOCKET A L A R M

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

